Dr. Reddy’s has expanded its commercial operations in Europe with the introduction of its range of generic drugs in France.
Dr. Reddy’s Laboratories has expanded its commercial operations in Europe with the introduction of its range of generic drugs in France. The first products, which include cancer drugs, anti-infectives, and antimycotics, will be made available in the hospital market in March 2017.
The company also recently launched select products of its hospital portfolio in Italy and Spain, and is looking to expand its business in these regions with the launch of anti-HIV products this year.
Dr. Reddy’s has a portfolio of injectables and complex generic drugs. The company currently has two R&D centres, one manufacturing, and a packaging and storage facility in Europe.
